Enzo Biochem, Inc.  

(Public, NYSE:ENZ)   Watch this stock  
Find more results for ENZ
-0.05 (-0.97%)
Sep 26 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 5.05 - 5.13
52 week 2.95 - 7.00
Open 5.09
Vol / Avg. 73,515.00/159,358.00
Mkt cap 231.86M
P/E 13.25
Div/yield     -
EPS 0.38
Shares 46.26M
Beta 1.50
Inst. own 65%
Oct 11, 2016
Q4 2016 Enzo Biochem Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 12, 2016
Enzo Biochem Inc at Rodman & Renshaw Global Investment Conference
Jul 12, 2016
Enzo Biochem Inc at Cantor Fitzgerald Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Apr '16) 2015
Net profit margin -8.00% -2.34%
Operating margin -9.51% -1.24%
EBITD margin - -0.09%
Return on average assets -10.78% -3.44%
Return on average equity -15.80% -5.74%
Employees 443 -
CDP Score - -


United States - Map
+1-516-7555500 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Enzo Biochem, Inc. (Enzo) is an integrated life science and biotechnology company, which is engaged in the research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally. The Company operates through three segments: Enzo Life Sciences, Enzo Clinical Labs and Enzo Therapeutics. Enzo Life Sciences segment manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers around the world. Enzo Clinical Labs segment provides diagnostic services to the healthcare community. Enzo Therapeutics segment conducts research and development activities for therapeutic drug candidates.

Officers and directors

Barry W. Weiner President, Chief Financial Officer, Principal Accounting Officer, Treasurer, Director
Age: 65
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Elazar Rabbani Ph.D. Chairman of the Board, Chief Executive Officer, Secretary
Age: 72
Bio & Compensation  - Reuters
James M. O'Brien Executive Vice President - Finance
Age: 49
Bio & Compensation  - Reuters
David C. Goldberg Vice President - Corporate Development, General Manager of Enzo Clinical Labs
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Dieter Schapfel M.D. Chief Medical Director
Age: 52
Bio & Compensation  - Reuters
Bernard L. Kasten Jr., M.D. Lead Independent Director
Age: 69
Bio & Compensation  - Reuters
Gregory M. Bortz Independent Director
Age: 46
Bio & Compensation  - Reuters
Dov Perlysky Independent Director
Age: 53
Bio & Compensation  - Reuters